136 related articles for article (PubMed ID: 27848884)
21. Small-molecule degraders of cyclin-dependent kinase protein: a review.
Yu B; Du Z; Zhang Y; Li Z; Bian J
Future Med Chem; 2022 Jan; 14(3):167-185. PubMed ID: 34939427
[TBL] [Abstract][Full Text] [Related]
22. Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine.
Schulze-Gahmen U; Brandsen J; Jones HD; Morgan DO; Meijer L; Vesely J; Kim SH
Proteins; 1995 Aug; 22(4):378-91. PubMed ID: 7479711
[TBL] [Abstract][Full Text] [Related]
23. Loop flexibility and solvent dynamics as determinants for the selective inhibition of cyclin-dependent kinase 4: comparative molecular dynamics simulation studies of CDK2 and CDK4.
Park H; Yeom MS; Lee S
Chembiochem; 2004 Dec; 5(12):1662-72. PubMed ID: 15505811
[TBL] [Abstract][Full Text] [Related]
24. Molecular models of protein kinase 6 from Plasmodium falciparum.
Manhani KK; Arcuri HA; da Silveira NJ; Uchôa HB; de Azevedo WF; Canduri F
J Mol Model; 2005 Dec; 12(1):42-8. PubMed ID: 16096806
[TBL] [Abstract][Full Text] [Related]
25. Inhibitors of Cyclin-Dependent Kinases: Types and Their Mechanism of Action.
Łukasik P; Baranowska-Bosiacka I; Kulczycka K; Gutowska I
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802080
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and in vitro biological evaluation of 2,6,9-trisubstituted purines targeting multiple cyclin-dependent kinases.
Zatloukal M; Jorda R; Gucký T; Řezníčková E; Voller J; Pospíšil T; Malínková V; Adamcová H; Kryštof V; Strnad M
Eur J Med Chem; 2013 Mar; 61():61-72. PubMed ID: 22770608
[TBL] [Abstract][Full Text] [Related]
27. How Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases?
Jorda R; Hendrychová D; Voller J; Řezníčková E; Gucký T; Kryštof V
J Med Chem; 2018 Oct; 61(20):9105-9120. PubMed ID: 30234987
[TBL] [Abstract][Full Text] [Related]
28. Structural Bioinformatics Approach of Cyclin-Dependent Kinases 1 and 3 Complexed with Inhibitors.
Saraiva LA; Veloso MP; Camps I; da Silveira NJ
Mol Inform; 2011 Mar; 30(2-3):219-31. PubMed ID: 27466775
[TBL] [Abstract][Full Text] [Related]
29. Cyclin-Dependent Kinase Inhibitors as Anticancer Therapeutics.
Law ME; Corsino PE; Narayan S; Law BK
Mol Pharmacol; 2015 Nov; 88(5):846-52. PubMed ID: 26018905
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of neuronal apoptosis by the cyclin-dependent kinase inhibitor GW8510: identification of 3' substituted indolones as a scaffold for the development of neuroprotective drugs.
Johnson K; Liu L; Majdzadeh N; Chavez C; Chin PC; Morrison B; Wang L; Park J; Chugh P; Chen HM; D'Mello SR
J Neurochem; 2005 May; 93(3):538-48. PubMed ID: 15836613
[TBL] [Abstract][Full Text] [Related]
31. Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016).
Di Giovanni C; Novellino E; Chilin A; Lavecchia A; Marzaro G
Expert Opin Investig Drugs; 2016 Oct; 25(10):1215-30. PubMed ID: 27606939
[TBL] [Abstract][Full Text] [Related]
32. A Photoaffinity Displacement Assay and Probes to Study the Cyclin-Dependent Kinase Family.
Grant EK; Fallon DJ; Eberl HC; Fantom KGM; Zappacosta F; Messenger C; Tomkinson NCO; Bush JT
Angew Chem Int Ed Engl; 2019 Nov; 58(48):17322-17327. PubMed ID: 31518032
[TBL] [Abstract][Full Text] [Related]
33. Structure and inhibitor specificity of the PCTAIRE-family kinase CDK16.
Dixon-Clarke SE; Shehata SN; Krojer T; Sharpe TD; von Delft F; Sakamoto K; Bullock AN
Biochem J; 2017 Feb; 474(5):699-713. PubMed ID: 28057719
[TBL] [Abstract][Full Text] [Related]
34. Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor.
Davies TG; Bentley J; Arris CE; Boyle FT; Curtin NJ; Endicott JA; Gibson AE; Golding BT; Griffin RJ; Hardcastle IR; Jewsbury P; Johnson LN; Mesguiche V; Newell DR; Noble ME; Tucker JA; Wang L; Whitfield HJ
Nat Struct Biol; 2002 Oct; 9(10):745-9. PubMed ID: 12244298
[TBL] [Abstract][Full Text] [Related]
35. High-resolution crystal structures of human cyclin-dependent kinase 2 with and without ATP: bound waters and natural ligand as guides for inhibitor design.
Schulze-Gahmen U; De Bondt HL; Kim SH
J Med Chem; 1996 Nov; 39(23):4540-6. PubMed ID: 8917641
[TBL] [Abstract][Full Text] [Related]
36. Toward understanding the structural basis of cyclin-dependent kinase 6 specific inhibition.
Lu H; Schulze-Gahmen U
J Med Chem; 2006 Jun; 49(13):3826-31. PubMed ID: 16789739
[TBL] [Abstract][Full Text] [Related]
37. Discovery of [4-Amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6- methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity.
Chu XJ; DePinto W; Bartkovitz D; So SS; Vu BT; Packman K; Lukacs C; Ding Q; Jiang N; Wang K; Goelzer P; Yin X; Smith MA; Higgins BX; Chen Y; Xiang Q; Moliterni J; Kaplan G; Graves B; Lovey A; Fotouhi N
J Med Chem; 2006 Nov; 49(22):6549-60. PubMed ID: 17064073
[TBL] [Abstract][Full Text] [Related]
38. Protein-Protein Interaction for the De Novo Design of Cyclin-Dependent Kinase Peptide Inhibitors.
Arumugasamy K; Tripathi SK; Singh P; Singh SK
Methods Mol Biol; 2016; 1336():59-66. PubMed ID: 26231708
[TBL] [Abstract][Full Text] [Related]
39. Potential Clinical Uses of CDK Inhibitors: Lessons from Synthetic Lethality Screens.
Vymětalová L; Kryštof V
Med Res Rev; 2015 Nov; 35(6):1156-74. PubMed ID: 26114963
[TBL] [Abstract][Full Text] [Related]
40. Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).
Malínková V; Vylíčil J; Kryštof V
Expert Opin Ther Pat; 2015; 25(9):953-70. PubMed ID: 26161698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
